|
🐜
|
Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers
21 auth.
J. Engelman,
Liang Chen,
X. Tan,
K. Crosby,
A. Guimaraes,
Rabi Upadhyay,
Michel Maira,
K. McNamara,
Samanthi A. Perera,
Youngchul Song,
...
L. Chirieac,
R. Kaur,
Angela Lightbown,
Jessica Simendinger,
Timothy Q Li,
R. Padera,
C. García-echeverría,
R. Weissleder,
U. Mahmood,
L. Cantley,
Kwok-kin Wong
|
10 |
2008 |
10
🐜
|
|
🐜
|
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
15 auth.
V. Serra,
B. Markman,
M. Scaltriti,
P. J. Eichhorn,
Vanesa Valero,
M. Guzman,
M. Botero,
E. Llonch,
F. Atzori,
S. Di Cosimo,
...
Michel Maira,
C. García-echeverría,
J. Parra,
J. Arribas,
J. Baselga
|
9 |
2008 |
9
🐜
|
|
🐜
|
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
9 auth.
G. Konstantinidou,
E. Bey,
A. Rabellino,
K. Schuster,
Michel Maira,
A. Gazdar,
...
A. Amici,
D. Boothman,
P. Scaglioni
|
7 |
2009 |
7
🐜
|
|
🐜
|
Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo
7 auth.
T. O'reilly,
M. Wartmann,
J. Brueggen,
P. Allegrini,
A. Floersheimer,
Michel Maira,
...
P. Mcsheehy
|
6 |
2008 |
6
🐜
|
|
🐜
|
NVP-BEZ 235 , a Dual PI 3 K / mTOR Inhibitor , Prevents PI 3 K Signaling and Inhibits the Growth of Cancer Cells with Activating PI 3 K Mutations
15 auth.
V. Serra,
B. Markman,
M. Scaltriti,
P. J. Eichhorn,
Vanesa Valero,
M. Guzman,
M. Botero,
E. Llonch,
F. Atzori,
S. Cosimo,
...
Michel Maira,
C. García-echeverría,
J. Parra,
J. Arribas,
J. Baselga
|
6 |
2008 |
6
🐜
|
|
🐜
|
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
8 auth.
A. Elfiky,
S. Aziz,
P. Conrad,
Summar F. Siddiqui,
W. Hackl,
Michel Maira,
...
C. L. Robert,
H. Kluger
|
5 |
2011 |
5
🐜
|
|
🐜
|
Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
17 auth.
L. Vaughan,
P. Clarke,
K. Barker,
Yvan H. Chanthery,
Clay Gustafson,
E. Tucker,
J. Renshaw,
F. Raynaud,
Xiaodun Li,
R. Burke,
...
Y. Jamin,
S. Robinson,
A. Pearson,
Michel Maira,
W. Weiss,
P. Workman,
L. Chesler
|
5 |
2016 |
5
🐜
|
|
🐢
|
Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials
17 auth.
Voliva Charles,
S. Pecchi,
M. Burger,
Tobi E. Nagel,
C. Schnell,
C. Fritsch,
S. Brachmann,
D. Menezes,
M. Knapp,
K. Shoemaker,
...
M. Wiesmann,
Kay Huh,
I. Zaror,
M. Dorsch,
W. Sellers,
C. García-echeverría,
Michel Maira
|
5 |
2010 |
5
🐢
|
|
🦁
|
Preclinical and Preliminary Clinical Activity of NVP-BKM120, an Oral Pan-Class I PI3K Inhibitor, in the Brain
10 auth.
Michel Maira,
C. Schnell,
P. Lollini,
C. Chouaid,
P. Schmid,
P. Nanni,
...
D. Lam,
E. Tomaso,
C. Massacesi,
J. Rodón
|
3 |
2012 |
3
🦁
|
|
🦁
|
Abstract 4497: NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models
13 auth.
Michel Maira,
D. Menezes,
S. Pecchi,
K. Shoemaker,
M. Burger,
C. Schnell,
C. Fritsch,
S. Brachmann,
Tobi E. Nagel,
W. Sellers,
...
C. García-echeverría,
M. Wiesmann,
Voliva Charles
|
3 |
2010 |
3
🦁
|
|
🦁
|
Biochemical, cellular and in vivo profiling of a new PI3K inhibitor from the imidazoquinoline series
Michel Maira
|
3 |
2007 |
3
🦁
|
